A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Active, not recruiting · NCT04616326 · Registry updated 2026-02-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine | Headache, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms | Active, not recruiting | Phase 3 | 2026-02-27 | NCT04616326 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Eli Lilly and Company | 370 |
88 results · Page 1 of 4
Research sites
Swipe the table sideways for more columns.